PAM
CYTK icon

Panagora Asset Management’s Cytokinetics CYTK Stock Holding History

Panagora Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44,635
Closed -$1.47M – 1174
2025
Q2 		$1.47M Sell
44,635
-2,719
-6% -$94.6K 0.01% 551
2025
Q1 		$1.9M Hold
47,354
– – 0.01% 524
2024
Q4 		$2.23M Sell
47,354
-31
-0.1% -$1.61K 0.01% 495
2024
Q3 		$2.5M Buy
+47,385
New +$2.64M 0.01% 497
2019
Q4 		– Sell
-54,313
Closed -$618K – 2485
2019
Q3 		$618K Sell
54,313
-30,923
-36% -$388K ﹤0.01% 1212
2019
Q2 		$959K Buy
85,236
+85,223
+655,562% +$822K ﹤0.01% 1155
2019
Q1 		$0 Hold
13
– – ﹤0.01% 2519
2018
Q4 		$0 Buy
+13
New +$95 ﹤0.01% 2472
2018
Q3 		– Sell
-97,813
Closed -$812K – 2423
2018
Q2 		$812K Sell
97,813
-919
-0.9% -$7.65K ﹤0.01% 1219
2018
Q1 		$711K Sell
98,732
-15
-0% -$129 ﹤0.01% 1275
2017
Q4 		$805K Buy
98,747
+57,311
+138% +$651K ﹤0.01% 1220
2017
Q3 		$601K Buy
+41,436
New +$566K ﹤0.01% 1295
2017
Q1 		– Sell
-11,313
Closed -$137K – 2390
2016
Q4 		$137K Sell
11,313
-83,025
-88% -$881K ﹤0.01% 1859
2016
Q3 		$866K Buy
94,338
+17,533
+23% +$183K ﹤0.01% 1245
2016
Q2 		$729K Sell
76,805
-140,211
-65% -$1.15M ﹤0.01% 1235
2016
Q1 		$1.53M Buy
217,016
+10,493
+5% +$76.7K 0.01% 956
2015
Q4 		$2.16M Sell
206,523
-13,276
-6% -$130K 0.01% 798
2015
Q3 		$1.47M Buy
219,799
+43,189
+24% +$295K 0.01% 870
2015
Q2 		$1.19M Buy
176,610
+23,772
+16% +$156K 0.01% 1017
2015
Q1 		$1.04M Hold
152,838
– – 0.01% 1055
2014
Q4 		$1.22M Buy
152,838
+77,261
+102% +$332K 0.01% 953
2014
Q3 		$266K Buy
75,577
+74,806
+9,702% +$314K ﹤0.01% 1530
2014
Q2 		$4K Hold
771
– – ﹤0.01% 2306
2014
Q1 		$7K Buy
+771
New +$6.97K ﹤0.01% 2286
2013
Q3 		– Sell
-16,022
Closed -$185K – 2318
2013
Q2 		$185K Buy
+16,022
New +$126K ﹤0.01% 1664

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Panagora Asset Management's CYTK Position: Q3 2025 in Review

Panagora Asset Management sold out of Cytokinetics (CYTK) in Q3 2025, closing a stake of 44,635 shares — an estimated $1.47M sold.

Panagora Asset Management first reported a position in CYTK in Q2 2013 and held it in 25 quarters. The position peaked at $2.5M in Q3 2024. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

  • Panagora Asset Management reported no remaining Cytokinetics position as of Q3 2025 after selling out during the quarter.
  • Panagora Asset Management sold 44,635 Cytokinetics shares in Q3 2025, an estimated $1.47M.
  • Panagora Asset Management first reported a position in Cytokinetics in Q2 2013 and held it in 25 quarters.
  • Panagora Asset Management's Cytokinetics position peaked at $2.5M in Q3 2024.
  • 380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on Panagora Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.